^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

anti-CD19 CAR-T therapy

i
Other names: anti-CD19 CAR-T therapy
Associations
Trials
Company:
Wuhan Bio–Raid
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
Associations
Trials
9ms
Effect of signal peptide optimized by site-directed mutagenesis on the function of chimeric antigen receptor T cells (PubMed, Sheng Wu Gong Cheng Xue Bao)
This study aimed to optimize the SP sequence by site-directed mutagenesis and investigate its impact on the killing function of CD19-CAR-T...In summary, this study revealed that increasing the N-terminal positive charge of the signal peptide can improve the expression efficiency of CAR and promote the killing of CD19+ target cells. These findings provide a scientific basis the optimization and clinical application of CAR structure.
Journal • CAR T-Cell Therapy • IO biomarker
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha)
|
anti-CD19 CAR-T therapy
over2years
Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma. (PubMed, Front Immunol)
The median doses of CD22 and CD19 CAR T cell infusions were 4.1 × 10/kg and 4.0 × 10/kg, respectively. Both the estimated 1-year progression-free and overall survival rates were 55.6%. Our preliminary results indicated that salvage therapy with CD19/CD22 CAR T cell infusion alone and that in combination with ASCT are effective in treating some adult patients with r/r Burkitt lymphoma.
Journal
|
CD19 (CD19 Molecule) • CD22 (CD22 Molecule)
|
anti-CD19 CAR-T therapy • anti-CD22 CAR-T therapy